ArticleLeukemia2023
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.
Open access · hybridAbstract readLetter
In one paragraph
Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 4 pooled it
19.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 4 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Exposure-Response Analyses of Ropeginterferon Alfa-2b in Essential Thrombocythemia.Journal of clinical pharmacology · 2026Pooled it
- Efficacy and safety of ropeginterferon in myeloproliferative neoplasms: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis.Annals of hematology · 2024Pooled it
- Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes.Blood advances · 2024Pooled it
- Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.International journal of cancer · 2025Trial
- Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera.International journal of hematology · 2024Trial
- Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera.Blood advances · 2024Trial
- Molecular Response, Event-Free Survival, and Treatment-Free Remission in Myeloproliferative Neoplasms: Update and Review with Insights from MPN Asia 2026.Current hematologic malignancy reports · 2026Review
- Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).Lancet regional health. Americas · 2026Article
- [Progress in the study of polycythemia vera in children].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Review
- Efficacy and Safety of Ropeginterferon Alfa-2b in Low-Risk Polycythemia Vera.Cancer research and treatment · 2026Article
- Between the classic hit and the modern sequel: transition dosing between peginterferon alfa-2a and ropeginterferon alfa-2b for myeloproliferative neoplasms.Annals of hematology · 2026Article
- Effective Treatment with Ruxolitinib and Ropeginterferon Alfa-2b for Refractory TAFRO-like Syndrome.Internal medicine (Tokyo, Japan) · 2026Article
- A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha.Leukemia · 2026Review
- Consensus on the use of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: a modified Delphi survey.International journal of hematology · 2026Article
- Cost-effectiveness analysis of ropeginterferon alfa-2b for the management of patients with polycythemia vera in Japan.International journal of hematology · 2026Article
- Why JAK2-mutated neutrophils deserve to be on center stage in polycythemia vera.Annals of hematology · 2026Article
- Long-term efficacy and safety of ropeginterferon alfa-2b under its HIDAT regimen for the treatment of polycythemia vera.Blood advances · 2026Article
- Plasma cfDNA and peripheral blood gDNA provide complementary information for molecular monitoring in myeloproliferative neoplasms.Frontiers in oncology · 2026Article
- Beyond Oncogenes: Selectively Targeting Whole-Tumor Cell Growth Regulation.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 13 institutions in 9 countries.
Heinz GisslingerDepartment of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University Vienna, Vienna, Austria. heinz.gisslinger@meduniwien.ac.at.
Christoph KladeAOP Health, Vienna, Austria.
Pencho GeorgievMedical University of Plovdiv, Plovdiv, Bulgaria.
Dorota KrochmalczykTeaching Unit of the Hematology Department, University Hospital in Krakow, Krakow, Poland.
Liana Gercheva-KyuchukovaClinical Hematology Clinic, Multiprofile Hospital for Active Treatment "Sveta Marina", Varna, Bulgaria.
Miklos EgyedDepartment of Internal Medicine II, Kaposi Mor County Teaching Hospital, Kaposvar, Hungary.
Petr DulicekDepartment of Clinical Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
Arpad IllesDepartment of Hematology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Halyna PylypenkoDepartment of Hematology, Regional Treatment and Diagnostics Hematology Centre, Cherkasy Regional Oncology Centre, Cherkasy, Ukraine.
Lylia SivchevaFirst Department of Internal Medicine, Multiprofile Hospital for Active Treatment - HristoBotev, Vratsa, Bulgaria.
Jiří MayerClinic of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
Vera YablokovaDepartment of Hematology, Yaroslavl Regional Clinical Hospital, Yaroslavl, Russia.
Kurt KrejcyAOP Health, Vienna, Austria.
Victoria EmpsonAOP Health, Vienna, Austria.ORCID http://orcid.org/0000-0003-3819-2370
Hans C HasselbalchDepartment of Hematology, Zealand University Hospital, Roskilde, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0003-3936-8032
Robert KralovicsDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0002-6997-8539
Jean-Jacques KiladjianUniversité de Paris, AP-HP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM, CIC1427, Paris, France.ORCID http://orcid.org/0000-0002-8121-438X
PROUD-PV Study Group
Inserm · FRMedical University of Vienna · ATCherkasy State Technological University · UAClinical Hospital No. 8 · RUKrakow Cardiovascular Research Institute · PLMedical University Plovdiv · BGNational Institute of Emergency Medicine "Pirogov" · BGSomogy Megyei Kaposi Mór Oktató Kórház · HUUniversity Hospital Brno · CZUniversity Hospital Hradec Králové · CZUniversity Hospital St. Marina · BGUniversity of Copenhagen · DKUniversity of Debrecen · HU
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Polycythemia VeraHumansProgression-Free SurvivalRecombinant ProteinsRecombinant Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.